Company to participate in 1:1 Investor Meetings on December 4, 2025 SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice... Read More

SARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its third quarter ended September 30, 2025. Recent Highlights Third quarter 2025 revenue was $3.5 million, a 19% increase over the third quarter of 2024. New accounts grew 31% in the third... Read More

Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma - among the most fatal cancers worldwide SARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug... Read More

Seasoned finance executive brings public company, capital markets and transaction experience to support next phase of growth SARATOGA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the appointment of David Garcia as Senior Vice President of Finance, effective... Read More

Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision... Read More

SARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc . (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, and Doug Atkinson, Head of Global Sales, will participate in the 4th Annual ROTH Healthcare Opportunities Conference, taking place on Thursday, October... Read More

SARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its second quarter ended June 30, 2025. Recent Highlights Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024. New accounts grew 75% in the second... Read More

Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on... Read More

SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began... Read More

SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected... Read More